Lansoprazole
Product Images NDC 55648-669

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 55648-669). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Wockhardt Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container Label (15 mg 1000c)

Label for Lansoprazole Delayed-Release Capsules, USP 15 mg, distributed by Wockhardt U.S.A. The label states the product contains 1000 capsules, each capsule is pink and green and contains 15 mg of lansoprazole as enteric-coated granules. It includes storage instructions and dispensing warnings, with manufacturer information listed as Wockhardt Limited, Mumbai, India.*

FDA Label Image

Container Label (30 mg 1000c)

Label for Lansoprazole Delayed-Release Capsules, USP 30 mg by Wockhardt Limited. The label states the capsule contains 30 mg of lansoprazole as enteric-coated granules and includes storage instructions, dispensing directions, and identification markings. The package contains 1000 capsules. Distribution and manufacturing locations are listed as the USA and Mumbai, India, respectively.*

FDA Label Image

Structure (Lansodrcapsrx M Figure 01)

Chemical structure of lansoprazole, showing its molecular framework including a benzimidazole ring, a sulfinyl group, and a substituted pyridine ring with a trifluoromethoxy group.*

FDA Label Image

Figure 1 (Lansodrcapsrx M Figure 02)

A line graph titled 'Mean Severity of Day Heartburn By Study Day For Evaluable Patients' comparing mean heartburn severity scores over approximately 60 days from treatment start. It includes three groups: placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD. Severity is rated from 0 (None) to 3 (Severe). Both Lansoprazole doses show a marked decrease in heartburn severity compared to placebo over time.*

FDA Label Image

Figure 2 (Lansodrcapsrx M Figure 03)

A line graph showing the mean severity of night heartburn over approximately 60 days for evaluable patients. The graph compares three groups: placebo, Lansoprazole 15 mg once daily, and Lansoprazole 30 mg once daily, with severity scale ranging from 0 (none) to 3 (severe).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.